Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

266
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
266
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.2K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.2K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

275
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
275
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

341
The pathophysiology of pneumonia involves the following steps:
341
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

227
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
227

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Depiction of Delirium in Contemporary Medical Television Dramas: A Descriptive Content Analysis.

Journal of the American Geriatrics Society·2026
Same author

Large Language Models Provide Accurate but Potentially Unsafe Answers to Multimodal Critical Care Medicine Board Review Questions.

Critical care medicine·2026
Same author

Pathogen-specific host responses define distinct pneumonia endotypes in the human lung.

bioRxiv : the preprint server for biology·2026
Same author

Impact of Livestreaming Pre-Clerkship Lectures: A Prospective Pilot with Multiyear Follow-up.

Medical science educator·2026
Same author

Prone Positioning in a North American Cohort of Hypoxemic Patients on Mechanical Ventilation.

Critical care medicine·2026
Same author

Mitochondrial L-2-hydroxyglutarate is a physiological signalling metabolite.

Nature·2026
Same journal

Defining Success and Failure In Prosthetic Joint Infections: A Meta-epidemiologic Study Toward A Core Outcome Set.

Open forum infectious diseases·2026
Same journal

A Call to Investigate the Association Between Histoplasmosis and Fatigue.

Open forum infectious diseases·2026
Same journal

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening Program.

Open forum infectious diseases·2026
Same journal

Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.

Open forum infectious diseases·2026
Same journal

Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024-2025 Observational Case-series.

Open forum infectious diseases·2026
Same journal

Persistent Dominance of Serotype 3 in Noninvasive Pneumococcal Disease in Belgium (2022-2025).

Open forum infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Jul 20, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.0K

An Adjudication Protocol for Severe Pneumonia.

Chiagozie I Pickens1, Catherine A Gao1, Justin Bodner1

  • 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Open Forum Infectious Diseases
|July 31, 2023
PubMed
Summary
This summary is machine-generated.

Developing a clinical end point protocol for severe pneumonia showed moderate agreement. Clinical cure by day 7-8 was linked to better patient outcomes, suggesting its validity in severe pneumonia research.

Keywords:
adjudicationclinicalend pointpneumoniasevere

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.3K
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

11.8K

Related Experiment Videos

Last Updated: Jul 20, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.0K
Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.3K
Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

11.8K

Area of Science:

  • Pulmonary and Critical Care Medicine
  • Clinical Trial Methodology
  • Infectious Diseases

Background:

  • Defining successful treatment for severe pneumonia is challenging due to potential bias.
  • The effectiveness of a structured protocol for determining meaningful clinical end points in severe pneumonia requires further investigation.

Purpose of the Study:

  • To develop and evaluate an adjudication protocol for severe bacterial and/or viral pneumonia.
  • To assess the reliability and validity of clinical end points in severe pneumonia management.

Main Methods:

  • A single-center prospective cohort study involving patients with severe pneumonia in the medical intensive care unit.
  • Independent review of pneumonia episodes by two, and if necessary, three pulmonary and critical care physicians.
  • Consensus review for unresolved discrepancies among adjudicators.

Main Results:

  • Moderate interobserver agreement (48.1% to 78.8%) was achieved with the adjudication protocol.
  • Lower agreement was associated with multiple pneumonia episodes and coinfections.
  • An adjudicated clinical cure by day 7-8 in bacterial pneumonia correlated with higher odds of live discharge (OR, 6.3; 95% CI, 3.5-11.6).

Conclusions:

  • A comprehensive adjudication protocol for severe pneumonia yielded only moderate interobserver agreement.
  • Clinical cure by day 7-8 appears to be a valid and meaningful end point for adjudication protocols.
  • This finding supports the use of early clinical cure as a surrogate for favorable outcomes in severe pneumonia studies.